Holen Sie sich die Stockscreener-App
6.80
3.43%
0.24
Schlusskurs vom Vortag:
$6.56
Offen:
$6.58
24-Stunden-Volumen:
255.08K
Relative Volume:
0.40
Marktkapitalisierung:
$324.11M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-59.85M
KGV:
-7.6775
EPS:
-0.8857
Netto-Cashflow:
$-54.54M
1W Leistung:
+3.75%
1M Leistung:
-5.50%
6M Leistung:
+274.86%
1J Leistung:
+479.91%
1-Tages-Spanne:
$6.52
$7.045
1-Wochen-Bereich:
$6.42
$7.29
52-Wochen-Spanne:
$1.05
$8.04
Climb Bio Inc Stock (CLYM) Company Profile
Firmenname
Climb Bio Inc
Sektor
Branche
Telefon
1-866-857-2596
Adresse
20 WILLIAM STREET, WELLESLEY HILLS
Compare CLYM vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLYM
Climb Bio Inc
|
6.785 | 313.36M | 0 | -59.85M | -54.54M | -0.8857 |
VRTX
Vertex Pharmaceuticals Inc
|
433.68 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
762.51 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.60 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
331.03 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.76 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Climb Bio Inc Stock (CLYM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-24 | Eingeleitet | B. Riley Securities | Buy |
| 2026-03-18 | Eingeleitet | Truist | Buy |
| 2026-03-11 | Eingeleitet | Raymond James | Strong Buy |
| 2026-03-05 | Eingeleitet | Wedbush | Outperform |
| 2026-02-13 | Eingeleitet | Piper Sandler | Overweight |
| 2025-10-16 | Eingeleitet | William Blair | Outperform |
| 2025-10-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-08-15 | Eingeleitet | Robert W. Baird | Outperform |
| 2025-06-06 | Eingeleitet | Oppenheimer | Outperform |
| 2025-05-22 | Eingeleitet | BTIG Research | Buy |
| 2024-12-02 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Climb Bio Inc Aktie (CLYM) Neueste Nachrichten
Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight - GlobeNewswire Inc.
Climb Bio, Inc. 8-K Filing Details: Company Information, Address, and Stock Exchange Listing (April 2026) - Minichart
Climb Bio announces departure of finance SVP and appointment of new accounting officer - Investing.com
Climb Bio's recently appointed CFO is unlikely to make a significant impact—what truly matters is the clinical data. - Bitget
Climb Bio Consolidates Financial Leadership After SVP Departure - tipranks.com
Climb Bio (CLYM) consolidates CFO and principal accounting officer roles - Stock Titan
Climb Bio (CLYM) price target increased by 34.43% to 15.67 - MSN
CLYM Stock Price, Quote & Chart | CLIMB BIO INC (NASDAQ:CLYM) - ChartMill
Piper Sandler initiates coverage of Climb Bio (CLYM) with overweight recommendation - MSN
Climb Bio, Inc. (NASDAQ:CLYM) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Climb Bio, Inc.Common Stock (NQ: CLYM - The Chronicle-Journal
Climb Bio (NASDAQ:CLYM) Raised to Strong-Buy at B. Riley Financial - MarketBeat
B Riley Securities initiates coverage of Climb Bio (CLYM) with buy recommendation - MSN
B. Riley Securities Initiates Climb Bio(CLYM.US) With Buy Rating, Announces Target Price $26 - Moomoo
B. Riley Financial Initiates Coverage on Climb Bio (NASDAQ:CLYM) - MarketBeat
B.Riley initiates Climb Bio stock with buy rating on kidney drug potential - Investing.com
B.Riley initiates Climb Bio stock with buy rating on kidney drug potential By Investing.com - Investing.com Australia
If You Invested $1,000 in Climb Bio (CLYM) - Stock Titan
Aug Breakouts: Is Climb Bio Inc forming a double bottom2026 Technical Patterns & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Climb Bio (NASDAQ:CLYM) Upgraded by Truist Financial to Strong-Buy Rating - MarketBeat
Is Climb Bio, Inc. (CLYM) Outperforming Other Medical Stocks This Year? - MSN
Climb Bio (CLYM) Receives 'Buy' Rating from Truist Securities | - GuruFocus
This Evommune Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Sahm
Truist initiates Climb Bio stock with buy rating on drug potential - Investing.com Australia
Truist initiates Climb Bio stock with buy rating on drug potential By Investing.com - Investing.com South Africa
Climb Bio (CLYM) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Climb Bio Highlights Budoprutug and CLYM116 Milestones, Sets Up “Rich Data Year” in 2026 - MarketBeat
HC Wainwright Has Pessimistic View of Climb Bio Q1 Earnings - Defense World
Pharma News: Will Climb Bio Inc benefit from green energy policiesMarket Risk Report & Growth-Oriented Investment Plans - baoquankhu1.vn
Targets Report: Can Climb Bio Inc sustain its profitability2026 Action & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Raymond James initiates coverage of Climb Bio (CLYM) with strong buy recommendation - MSN
What is HC Wainwright's Forecast for Climb Bio Q1 Earnings? - MarketBeat
Finanzdaten der Climb Bio Inc-Aktie (CLYM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Climb Bio Inc-Aktie (CLYM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Thomas Stephen Basil | Director |
Feb 26 '26 |
Sale |
7.01 |
16,313 |
114,289 |
154,657 |
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):